176 related articles for article (PubMed ID: 29906649)
21. Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1.
Yang C; Cai H; Zhu X; Zhang L; Li J
Eur J Med Chem; 2024 May; 271():116407. PubMed ID: 38663283
[TBL] [Abstract][Full Text] [Related]
22. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
23. Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.
Kikuchi H; Fujisaki H; Furuta T; Okamoto K; Leimkühler S; Nishino T
Sci Rep; 2012; 2():331. PubMed ID: 22448318
[TBL] [Abstract][Full Text] [Related]
24. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and bioevaluation of 1-phenylimidazole-4-carboxylic acid derivatives as novel xanthine oxidoreductase inhibitors.
Zhou H; Li X; Li Y; Zhu X; Zhang L; Li J
Eur J Med Chem; 2020 Jan; 186():111883. PubMed ID: 31761385
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
27. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
28. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
29. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Higa S; Shima D; Tomitani N; Fujimoto Y; Kario K
J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1713-1720. PubMed ID: 31556223
[TBL] [Abstract][Full Text] [Related]
30. Compounds containing trace element copper or zinc exhibit as potent hyperuricemia inhibitors via xanthine oxidase inactivation.
Li LZ; Zhou GX; Li J; Jiang W; Liu BL; Zhou W
J Trace Elem Med Biol; 2018 Sep; 49():72-78. PubMed ID: 29895374
[TBL] [Abstract][Full Text] [Related]
31. Pharmacophore modeling, molecular docking and molecular dynamics studies on natural products database to discover novel skeleton as non-purine xanthine oxidase inhibitors.
Peng J; Li Y; Zhou Y; Zhang L; Liu X; Zuo Z
J Recept Signal Transduct Res; 2018 Jun; 38(3):246-255. PubMed ID: 29843539
[TBL] [Abstract][Full Text] [Related]
32. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
[TBL] [Abstract][Full Text] [Related]
34. Virtual Screening and Multi-targets Investigation of Novel Diazine Derivatives as Potential Xanthine Oxidase Inhibitors Based on QSAR, Molecular Docking, ADMET Properties, Dynamics Simulation and Network Pharmacology.
Yi B; Sun J; Liu Y; Zhang Z; Wang R; Shu M; Lin Z
Med Chem; 2023; 19(7):704-716. PubMed ID: 36757039
[TBL] [Abstract][Full Text] [Related]
35. Anti-hyperuricemia activity and toxicity prediction of a novel xanthine oxidoreductase inhibitor.
Zhou L; Wei B; Wu L; Li J; Zhu B; Zhang L
Biomed Chromatogr; 2020 Feb; 34(2):e4727. PubMed ID: 31657461
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
37. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
